Abeona Therapeutics announced its management will participate in the Stifel 2026 Healthcare Conference on November 11 and the Jefferies Global Healthcare Conference on November 18. They will hold a fireside chat and presentations, with live webcasts available on their investor website. This engagement highlights Abeona's ongoing efforts to promote its portfolio of therapies for rare diseases, including its commercial-stage product ZEVASKYN and pipeline candidates ABO-801 and ABO-701. Investors can access replays of these events for further insights into the company's progress and strategy.
Abeona Therapeutics is actively engaging with investors through upcoming healthcare conferences, which may influence market interest. On Pluang, ABEO trades at USD 2.54 with no change in the last day and a market cap of $156.01 million. These figures are current as of Nov 10, 2026 19:42 WIB.
Abeona Therapeutics reported an 18% sequential increase in Q3 2026 net revenue for ZEVASKYN, reaching $13.5 million, with 15 patient treatments completed since launch. The company expanded its qualified treatment center network to eight sites and sec...
Abeona Therapeutics acquired ABO-801, a Phase 3-ready oral therapy candidate for eosinophilic esophagitis (EoE), from Ellodi Pharmaceuticals with a $20 million equity payment and no upfront cash. ABO-801 has FDA Orphan Drug and Fast Track designation...
